Several UC San Francisco scientists and clinicians will present their work confronting the coronavirus pandemic at the Precision Medicine World Conference (PMWC), titled “COVID-19: Disrupter of Biomedical Research and Healthcare."
The three-day virtual forum, to be held on Jan. 25-27, 2021, offers free registration here.
As the pandemic exploded, researchers at UCSF and around the world pivoted to use their expertise and technologies to attack COVID-relevant problems, and health care professionals responded in real time to the public health emergency that continues to escalate today.
Among the topics to be covered by the world’s leading scientists at the PMWC are:
The PMWC will honor Anthony Fauci, MD, director of the National Institute of Allergies and Infectious Diseases (NIAID), who has been a national leader in the fight against the coronavirus. Fauci was appointed director of NIAID in 1984, serving as a relentless crusader against some of most virulent public health threats. He oversees an extensive research portfolio of basic and applied research to prevent, diagnose, and treat established infectious diseases such as HIV/AIDS, respiratory infections, diarrheal diseases, tuberculosis and malaria, as well as emerging diseases such as Ebola, Zika and now, COVID-19.
UCSF Faculty to Highlight COVID-19 Response
Keith Yamamoto, PhD, vice chancellor for Science Policy and Strategy and director of Precision Medicine at UCSF, will serve as session chair on the first day of the PMWC, Yamamoto will be joined by colleagues from Vanderbilt University, Stanford University and Duke University to discuss how academic medicine transformed research and health care in response to the pandemic.
Kirsten Bibbins-Domingo, MD, PhD, MAS, vice dean for Population Health and Health Equity and a professor of Epidemilogy & Biostatistics at the UCSF School of Medicine, and will lead a session titled “Health Disparities in the COVID-19 Pandemic.” Panelists will include Diane Havlir, MD, chief of the UCSF Division of HIV, Infectious Disease and Global Medicine at Zuckerberg San Francisco General Hospital and Trauma Center. Both Bibbins-Domingo and Havlir both lead testing in San Francisco’s Mission District. The project aims to enhance the ability of San Francisco public health officials to detect and contain the spread of the virus among the heavily impacted Latinx community and essential workers in the Mission neighborhood.
Danielle Swaney, PhD, assistant professor of Cellular Molecular Pharmacology, who works with Nevan Krogan, professor of Cellular Molecular Pharmacology, will present “Discovery of SARS-CoV-2 Host-protein Targets for Antiviral Drug Repurposing.” They were part of an international team in six countries that studied the three lethal coronaviruses to identify commonly hijacked cellular pathways and detect promising targets for broad coronavirus inhibition.
Aashish Manglik, MD, PhD, an assistant professor of pharmaceutical chemistry, will also present his work at PMWC. Manglik is part of a team of researchers, including Peter Walter, PhD, professor of Biochemistry and Biophysics, that engineered a completely synthetic molecule that is among the most potent SARS-CoV-2 antivirals yet discovered. In its aerosol form, dubbed “AeroNabs,” these molecules could be self-administered with a nasal spray or inhaler. Used once a day, AeroNabs could provide powerful, reliable protection against SARS-CoV-2 until a vaccine becomes available.
Register online here
Monday, January 25 at 8:00am to 12:00amVirtual Event